Article Details

China's Kelun Pharma Jumps on Licensing New Cancer Drug to Merck Sharp & Dohme

Retrieved on: 2022-05-19 17:19:58

Tags for this article:

Click the tags to see associated articles and topics

China's Kelun Pharma Jumps on Licensing New Cancer Drug to Merck Sharp & Dohme. View article details on hiswai:

Excerpt

in its exclusive license and collaboration agreement with Merck Sharp & Dohme for overseas development rights of an experimental oncology treatment.

Article found on: www.goodwinlaw.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up